PurpleGap is biosimilar conversion intelligence for Medicare Part D. It joins CMS Part D prescribing data with the FDA Purple Book so market-access teams can see which prescribers and accounts are still writing reference biologics, how they compare with specialty and state peers, and where conversion opportunity is concentrated.
Teams use PurpleGap to prioritize outreach and formulary last-mile work rather than wrangling raw public files. The platform ranks opportunity at the prescriber, account, geography, and molecule-family level, and turns those views into watchlists, territory packs, and CRM-ready or API exports.
It is built for biosimilar manufacturers, PBM and Part D plan formulary teams, specialty pharmacy, and market-access consultants who take this work to their clients.
Core capabilities include prescriber opportunity lists with peer biosimilar gaps and opportunity dollars, state and geography ranking, FDA Purple Book launch alerts, watchlists and digest views, Open Payments context on opportunity rows, manufacturer competitive share packs, and territory or CRM export. Enterprise arrangements include unlimited list exports and an authenticated opportunities API.
